Background The aim of this study was to investigate the association between the results of the Recurrence Score (RS) assay and the clinical response to neoadjuvant endocrine therapy in postmenopausal women with breast cancer. Methods Core biopsy samples at baseline and posttreatment surgical samples were obtained from 80 and 77 of 116 patients, respectively, enrolled in the multicenter prospective study of neoadjuvant exemestane therapy (JFMC34-0601). The 21-gene assay was performed after appropriate manual microdissection. The estrogen receptor (ER), progesterone receptor, HER2 and Ki-67 were assayed by immunohistochemistry at a central laboratory. Clinical response was assessed based on the RECIST (Response Evaluation Criteria In Solid Tumors) guideline. Results Sixty-four core biopsy samples and 52 resection samples met the RS quality requirements. The clinical response rate in those patients with a low RS result (low RS group; 19/32, 59.4 %) was significantly higher than that in those patients with a high RS result (high RS group; 3/15, 20.0 %) (P = 0.015) and similar to that in patients with an intermediate RS result (intermediate RS group; 10/17, 58.8 %). The rates of breast-conserving surgery (BCS) were 90.6 % (29/32) in the low RS group, 76.5 % (13/17) in the intermediate RS group and 46.7 % (7/15) in the high RS group. The odds ratio for BCS adjusted for continuous 
Introduction
There are several potential advantages to neoadjuvant therapy of breast cancer in terms of improving outcomes in women with operable and inoperable early-stage disease [1, 2] . Both neoadjuvant chemotherapy and endocrine therapy have been shown to enable less extensive resection and improve rates of breast-conserving surgery (BCS) [3] [4] [5] [6] . The ACOSOG Z1031 trial, which compared three aromatase inhibitors (AIs) in neoadjuvant settings, showed that 51 % (81/159) of the patients who were designated candidates for mastectomy experienced downstaging to BCS [7] . Neoadjuvant endocrine therapy is now an acceptable option for postmenopausal patients with endocrine-responsive disease [8] .
Despite the use of standard biomarkers, the considerable heterogeneity of response to therapy still represents a challenge to clinicians in terms of choosing the most suitable neoadjuvant therapy. As such, tools to improve the identification of those patients who will respond to therapy would represent a major clinical advance. Although the Ki-67 labeling index (LI) shows some consistency in predicting response to chemotherapy, its ability to predict response to neoadjuvant endocrine therapy is controversial [9, 10] .
We previously reported results from a neoadjuvant exemestane study in postmenopausal women [11] . In that study, the target response rate was 51 % (59/116), and 40 (77 %) of 59 patients who would have required mastectomy were converted to BCS. Neither baseline Ki-67 LI nor changes in Ki-67 LI were associated with clinical response in the study.
The Oncotype DX Ò assay (Genomic Health, Redwood City, CA) has been shown to be able assess recurrence risk in women with hormone receptor-positive (HR?), lymph node-negative or -positive, early stage breast cancer who are treated with adjuvant endocrine therapy [12] [13] [14] [15] . It has also been shown to predict the likelihood of benefit from adjuvant chemotherapy [12, 16] . Accordingly, the assay is included in clinical guidelines for use in patients with HR? lymph node-negative disease; however, its applicability to HR? postmenopausal women with lymph node positive disease is considered controversial, pending results of the RxPONDER trial [8, [17] [18] [19] . Additionally, studies in the neoadjuvant setting have shown that the test can be used to predict the response to chemotherapy [20, 21] . More recently, a study suggested that the Recurrence Score (RS) value may predict responses to neoadjuvant endocrine therapy with either tamoxifen or anastrozole [22] . The Oncotype DX assay may improve the clinician's ability to discriminate between clinically similar tumors based on the tumor's underlying biology. Consequently, the aim of this study was to investigate the clinical usefulness of the RS assay results in the prediction of response to neoadjuvant endocrine therapy.
Methods

Study design
This was a prospectively designed study using archived tumor tissues from the previously conducted JFMC34-0601 study. The primary objective was to assess the association between the results of the RS assay at baseline and clinical response, by comparing the response rates between patients with a low RS result (\18; low RS group) and those with a high RS result (C31; high RS group). Secondary objectives included assessment of the associations of continuous baseline RS, quantitative estrogen receptor (ER) by reverse transcriptase (RT)-PCR and Ki-67 with clinical response and with BCS, as well as associations of changes from baseline to post-treatment values of these markers with clinical response. The study protocol was approved by the Ethics Committee of each participating institution. Informed consent was obtained from all patients. The study was performed in accordance with the Helsinki Declaration.
Patient cohort and tumor samples
Eligibility criteria for the parent JFMC34-0601 study included age 55-75 years, ER? and stage II or IIIa invasive breast cancer (T2-3, N0-2, M0). Patients were confirmed positive for ER or progesterone receptor (PgR) by immunohistochemistry (C10 % nuclear staining). The study treatment was 25 mg/day exemestane for 16 weeks, with a possible 8-week extension based on the assessment of clinical response. Patients with progressive disease (PD) were withdrawn from the study. At week 24, patients underwent surgery, except those with PD, who had the option of selecting another treatment approach.
Clinical outcomes measures
Clinical response was assessed by comparing the longest diameter of the target lesions with the baseline measurement, based on the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.0, by caliper measurement of palpable lesions and ultrasound as previously described [11] . Briefly, complete response (CR) was defined by the disappearance of all target lesions; partial response (PR) by at least a 30 % decrease in the sum of diameters of the target lesions; PD by at least a 20 % increase in the sum of diameters of the target lesions; stable disease (SD) by neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Biomarker assessments
The Oncotype DX Ò 21-gene assay was performed on core biopsy and resection samples by Genomic Health [14] .
Immunohistochemistry assays of Ki-67, ER and PgR were performed at one central location and the results assessed by three independent pathologists as described previously [11] . In brief, immunohistochemistry staining was performed using a Histofine kit (Nichirei, Tokyo, Japan). Ki-67 was stained using the following antibody dilution: 1:100 (Dako, Glostrup, Denmark), and the Ki-67 LI was obtained by counting 500-1,000 tumor cells at the sites of hot spots. Ki-67 groups were defined post hoc as \10, 10-30 and [30 %, respectively. ER and PgR immunoreactivity were scored according to Allred's procedure.
Expression of HER2 was determined by the HercepTest (Dako, Glostrup, Denmark). Positive HER2 status was defined as either 3? or 2? with confirmed c-erbB2 gene amplification by the fluorescence in situ hybridization (FISH) test.
Statistical analyses
Analyses of baseline markers included all patients with an evaluable RT-PCR result from core biopsies. Analyses of changes from baseline to post-treatment markers included the subset of patients with results from both core biopsies and surgical resections. Changes in continuous markers were defined as ''post-treatment value-pre-treatment value''. In the primary analysis, the rates of clinical response were compared between the high and low baseline RS groups using Fisher's exact test. Logistic regression models were fit to both clinical response and surgery type. Odds ratio (OR) estimates are presented with Wald p values and 95 % confidence intervals (CIs). All P values are two-sided. In exploratory analyses, the Spearman rank correlation coefficient (and associated 95 % CI) was calculated for the baseline continuous RS and either the post-treatment RS or baseline continuous Ki-67 as determined by immunohistochemistry. A paired t test was applied to compare the baseline and post-treatment RS values. A two-sample t test was used to compare the percentage reduction in tumor size between the high and low RS groups. Fisher's exact test was used to compare the conversion rate from mastectomy to BCS among risk groups.
Results
A total of 116 patients were enrolled in JFMC34-0601 between March 2006 and December 2007, of whom 102 completed 24 weeks of neoadjuvant exemestane treatment [11] . Core biopsy and resection samples were obtained for 80 (69 %) and 77 (66 %) patients, respectively. Of the 157 samples sent for Oncotype DX testing, two were deemed ineligible based on the blinded Genomic Health pathology review, insufficient RNA (\375 ng) was extracted from 18 samples (15 core biopsy and 3 resection samples), and standard quality metrics were not met for eight samples (all resections). This left 64 core biopsy samples, of which 52 had matching resection samples with evaluable RT-PCR results.
Baseline characteristics and clinical outcomes for the 64 patients are shown in Table 1 . Forty-nine (76.6 %) patients had BCS, and 32 patients (50 %) had been candidates for BCS before the treatment. Four patients refused surgery after exemestane therapy and are treated as not BCS patients.
In the primary analysis, the clinical response rate in the low RS group (19/32, 59.4 %) was significantly higher than that in the high RS group (3/15, 20.0 %) (P = 0.015) ( Table 2 ). The clinical response rate in the intermediate risk group (10/17, 58.8 %) was similar to that in the low risk group. Logistic regression revealed that the OR for clinical response between the intermediate and low RS groups was 0.977 (95 % CI 0.296-3.233, P = 0.970) and that the OR between the high and low RS groups was 0.171 (95 % CI 0.040-0.728, P = 0.017). In an exploratory analysis, the percentage reduction in tumor size determined by ultrasound was compared between the low and high RS groups. Patients in the low RS group showed an average reduction in tumor size of 31.8 % while those in the high RS group showed an average reduction of 12.5 %; this difference was significant between the groups (P = 0.045). The average reduction (27.6 %) in patients in the intermediate risk group was similar to that in the low risk group.
When treated as a continuous variable, the baseline RS Score was significantly associated with clinical response in a logistic regression analysis (P = 0.042; Table 3 ). There was a trend between continuous baseline ER as determined by RT-PCR and clinical response (P = 0.076). Continuous baseline Ki-67 by IHC was not associated with clinical response (P = 0.273).
The associations between changes from baseline to posttreatment values of continuous markers and clinical response were examined in logistic regression analyses. Changes in the RS, ER as determined by RT-PCR, and Ki-67 as determined by IHC were not associated with clinical response (P = 0.240, 0.343 and 0.629, respectively).
Analysis of the RS categories and BCS is shown in Table 2 . The OR for BCS between the intermediate and low RS groups was 0.336 (95 % CI 0.066-1.722, P = 0.19) and that between the high and low RS groups was 0.091 (95 % CI 0.019-0.432, P = 0.003). The logistic regression analyses of continuous baseline RS, ER by RT-PCR and Ki-67 by IHC with BCS are shown in Table 3 . The continuous baseline RS was significantly associated with BCS in both the unadjusted (p = 0.001) and covariate-adjusted (for tumor size and PgR) (P = 0.004) analyses. The continuous baseline ER by RT-PCR was also significantly associated with BCS in both the unadjusted (P = 0.001) and covariate-adjusted (P = 0.023) analyses. Continuous baseline Ki-67 by IHC was significantly associated with BCS in the unadjusted analysis (P = 0.024) but lost its significance when adjusted for tumor size and PgR (P = 0.060). When both the continuous RS values and continuous Ki-67 were included in the logistic regression model for BCS, the RS retained its statistical significance (P = 0.012) whereas Ki-67 did not (P = 0.868). The conversion rate from mastectomy planned at baseline to BCS performed after the treatment was 88 % (15/17) in the low RS group, 70 % (7/10) in the intermediate RS group and 20 % (1/5) in the high RS group. The rate was significantly different among groups (P = 0.010).
The associations between RS and Ki-67, and their respective and joint associations with BCS were examined in exploratory analyses. Figure 1a shows a scatterplot of baseline Ki-67 as determined by IHC versus the baseline RS results. The Spearman correlation coefficient was 0.672 (95 % CI 0.506-0.785). All patients with PD had a high RS (Fig. 1a) . No statistically significant difference was observed between baseline and post-treatment RS values (P = 0.484). A scatterplot is shown in Fig. 1b . The Spearman correlation analysis showed a high correlation (correlation coefficient 0.745, 95 % CI 0.592-0.846).
Discussion
In this study, we demonstrated the predictive value of the RS results for response to neoadjuvant endocrine therapy. Among our patient cohort, those with low scores showed a better response to neoadjuvant endocrine therapy than those with high scores. Since patients with high RS results have been shown to benefit from chemotherapy, the 21-gene assay may provide additional information that could facilitate the selection of neoadjuvant treatment with endocrine therapy for cancer patients with a low RS and chemotherapy for those with a high RS.
ER Allred scores have been reported to correlate with response rates to neoadjuvant letrozole or tamoxifen. The P024 trial of neoadjuvant letrozole or tamoxifen showed that tumors with low ER Allred scores still responded to letrozole [23] . Conversely, some tumors with higher ER levels did not respond to endocrine therapy [23, 24] . Gene expression-based profiles categorize HR?, HER2-breast cancers into two subtypes: luminal-A and -B [25] . However, the classification, which is based on PAM50, has been reported not to relate to clinical response or the likelihood of BCS after neoadjuvant AI treatment [7] .
In our study, the RS was the only predictive factor for clinical responses to neoadjuvant endocrine therapy and the most potent predictive factor for BCS in the covariateadjusted analysis. These results are consistent with those from other studies which suggest that a low RS can predict benefit from endocrine therapy [22, 24] . The study by Kim et al. [24] compared the outcomes of the tamoxifen and Our results indicate that the values of the RS before and after endocrine therapy were highly correlated. Since a number of studies have suggested that post-treatment biomarkers such as Ki-67 LI and ER have better prognostic values than pre-treatment biomarkers, post-treatment biomarkers are receiving increasing interest in clinical trials as a tool for patient stratification [26] [27] [28] . Dowsett et al. [26] reported the results of an unplanned, exploratory investigation of the relationship between posttreatment Ki-67 (2 weeks) and recurrence-free survival (RFS) using archived tumors from the IMPACT study. Their results indicate that post-treatment Ki-67, larger baseline tumor size and post-treatment ER level are significantly correlated with DFS. Ellis et al. [27] analyzed the ability of post-treatment Ki-67 and other factors (tumor size, grade, nodal status, and post-treatment ER expression) to predict RFS and breast cancer-specific survival using archived tumors from the P024 study. Another interesting study (ACOSOG Z1031, Cohort B) has been conducted to determine whether patients with a high Ki-67 value after 2 weeks of neoadjuvant AI treatment show a higher than expected pathogenic CR rate to neoadjuvant chemotherapy than would be typically observed for those patients with unselected ER-rich tumors. The results will tell us whether an assessment of Ki-67 2 weeks after neoadjuvant AI treatment will be useful for the identification of a chemotherapy-sensitive subgroup of ER? tumors. However, even if this is the case, intervention of a 2-week AI treatment and re-biopsy are necessary. Although further investigations are needed, the comparative stability of the RS would improve the overall decision-making process regarding the complete treatment before the initiation of treatment.
The main limitation of this was its small sample size. The availability of tumor samples from the parent study was limited and recovery of mRNA was not uniformly adequate. Further investigation in larger prospective studies would better define candidates for neoadjuvant endocrine therapy. Another limitation was the absence of any assessment of lymph node response. Although nodal response is clinically relevant, one of the major purposes of neoadjuvant endocrine therapy is improvement in surgical outcome. That said, however, the clinical response at the primary site and the BCS rate are also of clinical importance for the assessment of the effect of neoadjuvant endocrine therapy.
In conclusion, this study showed that RS results have predictive value for the clinical response to neoadjuvant exemestane therapy. The 21-gene assay would appear to be a promising tool for providing useful information to guide the clinician in choosing neoadjuvant treatment for systemic therapy, with neoadjuvant endocrine treatment for patients with low RS disease and neoadjuvant chemotherapy treatment for patients with high RS disease. 
